Background: Off-label use of gabapentinoids is common among patients admitted to hospital
medical wards, who are at risk of adverse drug events. In this study, we will assess if …

Gabapentinoid prescriptions are increasing in North America, with frequent off‐label use
despite limited proven efficacy. This retrospective cohort study describes prescribing trends …

The emerging issue of rising gabapentinoid misuse is being recognized alongside the lack
of current evidence supporting the safe and effective deprescribing of gabapentinoids. This …

Background Sales visits by pharmaceutical representatives (“drug detailing”) are common,
but little is known about the content of these visits or about the impact of visit characteristics …

Three years after gabapentin received US Food and Drug Administration (FDA) approval in
1990 for epilepsy, case reports and animal studies emerged announcing its potential in the …

Objective To evaluate indications for gabapentinoid prescription at an academic medical
center. Patients and Methods We retrospectively reviewed patients aged 18 years or older …

Objective: The objective of the study was to explore the experiences of physicians
prescribing gabapentin off label. Methods: We used a case study approach to explore the …

OBJECTIVES:(1) Describe the relevance of off-label use of gabapentin to managed care
pharmacy;(2) summarize recent FDA warnings and media reports related to off-label …

Increasing gabapentinoid use has raised concerns of misuse and abuse in the United States
(US). Little is known about the characteristics of gabapentinoid use in general clinical …

Background There is good evidence of selective outcome reporting in published reports of
randomized trials. Methods We examined reporting practices for trials of gabapentin funded …